Penn Davis McFarland’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Penn Davis McFarland’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-295,449	Closed	-$204K	–	50
2020 Q4	$204K	Sell	295,449 -2,838	-1%	-$6.04K	0.04%	43
2020 Q3	$671K	Buy	298,287 +95,027	+47%	+$271K	0.17%	30
2020 Q2	$728K	Sell	203,260 -1,004	-0.5%	-$3.62K	0.2%	31
2020 Q1	$776K	Sell	204,264 -174	-0.1%	-$573	0.27%	26
2019 Q4	$615K	Buy	+204,438	New	+$532K	0.18%	27

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Penn Davis McFarland's BMY.RT Position: Q1 2021 in Review

Penn Davis McFarland sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 295,449 shares — an estimated $204K sold.

Penn Davis McFarland first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $776K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Penn Davis McFarland reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Penn Davis McFarland sold 295,449 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $204K.
Penn Davis McFarland first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Penn Davis McFarland's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $776K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Penn Davis McFarland's 13F filing for Q1 2021, filed 21 Apr 2021.